[Acid related diseases progress in 2007]

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Gastroesophageal reflux disease (GERD) management strategies.
• Helicobacter pylori (H. pylori) infection treatment protocols.
• Nonsteroidal anti-inflammatory drug (NSAID)-induced gastroduodenal complications.

Purpose of the Study:

• To review current treatment guidelines for reflux disease.
• To evaluate the efficacy of different therapeutic approaches for H. pylori infection.
• To assess the role of proton pump inhibitors (PPIs) in NSAID-treated patients.

Main Methods:

• Review of existing literature and clinical guidelines.
• Analysis of treatment outcomes for GERD, H. pylori, and NSAID-induced lesions.
• Comparison of PPIs, surgical interventions, and combination therapies.

Main Results:

• Proton pump inhibitor (PPI) therapy remains the first-line treatment for reflux disease, with surgery as a second-line option.
• Surgical efficacy for reflux disease diminishes over time, with many patients requiring PPIs within ten years.
• Triple therapy is the preferred treatment for H. pylori infection; sequential treatment is recommended for persistent infections.
• PPIs are effective in preventing gastroduodenal lesions and treating dyspeptic symptoms in patients taking NSAIDs or COX-2 inhibitors.

Conclusions:

• Current treatment paradigms for reflux disease are well-established, with PPIs as the cornerstone therapy.
• Management of H. pylori infection requires tailored approaches based on initial treatment response.
• Proton pump inhibitors play a crucial role in mitigating gastrointestinal side effects associated with NSAID and COX-2 inhibitor use.